Trial Profile
A Randomized Phase II Study of Lenvatinib Versus Doxorubicin in Second Line Advanced or Recurrent Endometrial Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2017
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Doxorubicin
- Indications Endometrial cancer
- Focus Therapeutic Use
- 02 Jan 2017 New trial record